Skip to main content
IPSC logo

IPSC · Century Therapeutics, Inc. · Executive Compensation

Track IPSC — free
$1.29 -0.10 (-6.88%)
Market Cap
$250.60M
Shares
181.60M
Volume · Nov 19 109.88K Avg daily vol (3M) 738.85K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

No Compensation Data

No Summary Compensation Table has been imported from this company's proxy statements yet.

Executive changes

Person Change Filed
Joseph Truitt Appointed 2026-09-09
Carlo Rizzuto, Ph.D.
“Dr. Rizzuto’s decision to resign was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2025-12-29
Dr. Han Lee Appointed 2025-12-09
Dr. Martin Murphy Appointed 2025-12-09
Brent Pfeiffenberger, Pharm.D. Appointed 2025-08-14
Douglas Carr Appointed 2025-07-07
Adrienne Farid, Ph.D. Terminated 2025-07-07
Morgan Conn, Ph.D. Terminated 2025-07-07
Morgan Conn, Ph.D. Appointed 2024-09-26
Michael C. Diem, M.D.
“Dr. Diem’s decision to resign from the Company was not the result of any disagreement with the Company on matters relating to the Company’s operations, policies or practices.”
Resigned 2024-01-19
Gregory Russotti Appointed 2023-11-14
Brent Pfeiffenberger Appointed 2023-11-14
Brent Pfeiffenberger Appointed 2023-11-14
Michael Diem Appointed 2023-04-17
Gregory Russotti Appointed 2023-04-17
Osvaldo Flores, Ph.D.
“There was no disagreement between Dr. Flores and the Company on any matter related to the Company’s operations, policies or practices that led to Dr. Flores’ resignation from the Board.”
Resigned 2023-04-17
Osvaldo Flores, Ph.D.
“There was no disagreement between Dr. Flores and the Company on any matter related to the Company’s operations, policies or practices that led to Dr. Flores’ resignation from the Board.”
Resigned 2023-04-17
Timothy P. Walbert Appointed 2022-10-03
Daphne Quimi Appointed 2022-10-03
Eli Casdin Resigned 2022-10-03

Leadership

Key facts CIK 1850119 CUSIP 15673T100 13F (30d) 115 filings 99 filers Visit website Investor relations